Palantir–NHS training debate
A debate erupted over Palantir’s NHS deal after posts noted the contract doesn’t sell patient data but could still let AI models be trained on valuable health datasets. Social threads summarized the arrangement as enabling model training access without direct data sales, and that distinction is driving privacy and governance concerns online (x.com) (x.com).
The fight over Palantir’s National Health Service deal has turned on a narrow point: the contract says patient data is not being sold, but critics say access for building artificial intelligence tools can still carry value. (england.nhs.uk) The platform at the center of the dispute is the National Health Service Federated Data Platform, a cloud software system awarded to a Palantir-led consortium on November 22, 2023. Contracts Finder lists the awarded contract at £182,242,760, with National Health Service England saying spend could rise to a forecast £330 million as services are used. (contractsfinder.service.gov.uk) National Health Service England says the Federated Data Platform is “National Health Service-controlled,” and says each National Health Service trust and integrated care board remains the data controller for its own local instance. Its public explainer says patient data stays in the United Kingdom region, access is audited, and the contract includes “step in rights” so the National Health Service can take control in an extreme event. (england.nhs.uk) Artificial intelligence systems learn from examples in the same way spam filters learn from labeled emails. National Health Service guidance says training a model can involve taking data from health records and making it available to developers working with the National Health Service when the purpose is future care rather than a patient’s own treatment. (transform.england.nhs.uk) That distinction is where the current argument sits. A company does not need to buy a dataset outright to benefit from it if staff or contractors can use the records, or records-derived outputs, to improve a model that can later be reused elsewhere; that is an inference from how model training works and from National Health Service guidance on data access for development. (transform.england.nhs.uk) National Health Service England has tried to answer that concern with contract language around control, security, and intellectual property. Its contract explainer says “intellectual property for NHS funded services remain with the NHS,” and says vendor lock-in is limited through a seven-year term, exit planning, and migration standards. (england.nhs.uk) The contract itself includes sections on “Authority Data and Security Requirements” and on intellectual property and licences, which is why campaigners have focused on exactly what Palantir staff can do inside the system rather than on a simple question of sale or no sale. The public attachment on Contracts Finder shows those clauses are part of the signed November 2023 agreement. (contractsfinder.service.gov.uk) The politics around the platform have been building for months. In March 2026, The BMJ reported that a coalition of rights groups, patient advocates, and unions urged hospitals in England to refuse the software, while Digital Health reported warnings that the contract could enable harmful uses of sensitive public data; Palantir said it had “no intention of and no means” to use the data in the way critics suggested. (bmj.com) (digitalhealth.net) National Health Service England, meanwhile, says the platform is already being used to manage waiting lists, schedule operations, and support service planning across trusts, integrated care boards, and the national system. Palantir’s own United Kingdom healthcare page describes the system as a way to link data already collected for care where legal sharing agreements are in place. (england.nhs.uk) (palantir.com) So the argument is no longer just over whether the National Health Service “sells” patient data. It is over whether a public health system can let a private supplier work around rich clinical datasets, even under National Health Service control, without turning that access into a lasting advantage in artificial intelligence. (england.nhs.uk) (transform.england.nhs.uk)
